## Contents

1. **Forewords** ........................................... 3  
   From the SMHS Chief Executive .......... 3  
   Acknowledgements ............................. 4  
   Executive summary ............................ 5  

2. **Research environment** .................... 7  

3. **Overview of SMHS research activity** 8  

4. **Research translation** ....................... 9  

5. **Fiona Stanley Fremantle Hospitals Group** .......................... 10  
   Allied Health ..................................... 11  
   Anaesthetics ..................................... 15  
   Burns ............................................. 17  
   Cardiology ....................................... 24  
   Emergency Medicine ........................... 27  
   Endocrinology and Diabetes ............... 30  
   Gastroenterology ............................... 37  
   Haematology ..................................... 43  
   Intensive Care Unit ............................ 45  

   Medical Oncology .............................. 47  
   Neurology ....................................... 51  
   Orthopaedics .................................... 53  
   Perinatal Mental Health ..................... 54  
   Radiology ....................................... 56  
   Renal ............................................. 56  
   Respiratory Medicine ....................... 58  
   Rheumatology ................................... 60  
   Urology ......................................... 64  

6. **Rockingham Peel Group** .................... 66  
   Anaesthetics ..................................... 67  
   Diabetes and Endocrinology ............... 67  
   Emergency Department ....................... 68  
   Intensive Care Unit ............................ 69  
   Mental Health ................................... 70  
   Orthopaedics .................................... 71  

7. **Appendix 1: Report template** ............ 72  

8. **Appendix 2: Data source** .................. 73
Forewords

This inaugural South Metropolitan Health Service (SMHS) Research Report describes the research activity occurring in the Fiona Stanley Fremantle Hospital Group (FSFHG) and Rockingham Peel Group (RkPG), in the 2015 and 2016 calendar years.

Subsequent research reports will be annual, based on research activity during the prior calendar year i.e. the 2017 report will be published in March 2018. The request and submission process and report template will be refined for the 2017 report, following lessons learnt during the development of this inaugural report.

The Heads of Service (HoS) were requested to provide input into this report in conjunction with their departmental researchers, based on a brief research report template (Appendix 1). The submissions received have been amalgamated into service descriptions, rather than based on individual researchers, and some include collaborative multi-disciplinary team research activities.

From the SMHS Chief Executive

This inaugural report showcases the amount and quality of research activities within SMHS during 2015 and 2016, of which we should all be very proud. This was a time of immense organisational change due to the commissioning and opening of Fiona Stanley Hospital and the reconfiguration of seven other SMHS hospitals and health services.

Research is pivotal to SMHS and its local community, and will often have a broader reach nationally and internationally, as research is translated into practice to enhance and improve patient safety and quality of care.

As we develop our research strategy for the next few years, we recognise the existing skills, expertise and knowledge within the organisation, which we can build on to create a vibrant, energetic research community that focuses on real translation of research findings to the patients bedside or to improve organisational policies and / or outcomes.

SMHS fosters a culture of research inclusivity, where all professions and grades of staff are encouraged to conduct research across all our hospitals and health services, and have the support and infrastructure to conduct good quality research.

Mr Paul Forden
A/Chief Executive
South Metropolitan Health Service
Acknowledgements

This inaugural Research Report was developed with contributions from:

- Researchers from multiple departments as detailed within this report.
- Heads of Service, Clinical Trials Coordinators and administrative staff.
- SMHS Research, Ethics and Governance (REG) Unit team members:
  - Nola Mammatt, Coordinator Research Governance
  - Selina Metternick-Jones, Compliance Monitoring and Education Officer.
- REG Unit database analysis:
  - Mark Morgan, Senior Program Management Officer, SMHS Program Management Office (PMO).
- SMHS Research Strategy Steering Committee members:
  - Geraldine Carlton, Executive Director Transformation, SMHS (Chair)
  - Dr Sally Bradley, Director of Clinical Services, RkPG
  - Dr Paul Cannell, CoDirector Service 1, FSFHG
  - Dr Megan Galbally, Consultant Peri-Natal Mental Health, FSFHG
  - Dr Paul Mark, Director of Clinical Services, FSFHG
  - Professor Merrilee Needham, HoD Neurology, FSFHG
  - Professor John Olynyk, HoD Gastroenterology & Hepatology, FSFHG, and Director of Research Development, SMHS
  - Dr Jamie Rankin, HoD Cardiology, FSFHG
  - Professor Fiona Wood, Head of State Burns Service, FSFHG
  - Melanie Wright, Project Coordinator, SMHS.
Executive summary

The South Metropolitan Health Service (SMHS) Board has outlined research as a key enabler to deliver on its strategic priority of **Excellence in the delivery of safe, high quality clinical care**.¹

It is also recognised that research is a pivotal enabler of the other four strategic priorities of SMHS:

- Provide a great patient experience
- Engage, develop and provide opportunities for our workforce
- Strengthen relationships with our community and partners
- Achieve a productive and innovative organisation which is financially sustainable.

The attraction and retention of credible researchers is extremely important to SMHS, as “research is fundamental to achieve excellence in care and improve patient and consumer outcomes”.²

In 2015 and 2016, the majority of research in SMHS has been conducted at Fiona Stanley Hospital (FSH). Nonetheless, researchers at Fremantle Hospital (FH) and Rockingham General Hospital (RGH) have been active in the research environment and are keen to further expand their research capabilities and scope; noting that there is currently no formal research support in the general hospital environment.

This report showcases research activity in FSHG and RkPG and is a testament to the passion of our researchers and is worthy of celebration. SMHS is currently developing a formal research strategy to support our committed researchers and spread the breadth and depth of research being undertaken across our services.

The submissions to this report were predominantly from medical staff, and demonstrate a highly active research community (242 projects; 353 publications), with an ability to attract grants and funding from a variety of sources.

There were 190 ethics approvals in 2015, which increased to 205 in 2016. There were 369 governance approvals in 2015, compared to 211 in 2016; the inflation in 2015 is due to the migration of research projects from other sites to FSH during commissioning.

Table 1 below provides a high level summary of research activity by group and specialty / department / service for the 2015 and 2016 calendar years, as reported by the researchers or Heads of Service. This is not a representation of all the research activities undertaken in SMHS, as the submissions to this report were voluntary.

“research is fundamental to achieve excellence in care and improve patient and consumer outcomes”

---

¹ SMHS Strategic Plan 2017–2020
² Melbourne Health
Table 1: Research activity by group, and specialty / department / service

**Fiona Stanley Fremantle Hospitals Group (FSFHG)**

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allied Health</td>
<td>6</td>
<td>20</td>
</tr>
<tr>
<td>Anaesthetics</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>Burns</td>
<td>17</td>
<td>80</td>
</tr>
<tr>
<td>Cardiology</td>
<td>20</td>
<td>14</td>
</tr>
<tr>
<td>Emergency Medicine</td>
<td>4</td>
<td>25</td>
</tr>
<tr>
<td>Endocrinology and Diabetes</td>
<td>15</td>
<td>64</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>15</td>
<td>38</td>
</tr>
<tr>
<td>Haematology</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>Intensive Care Unit</td>
<td>6</td>
<td>13</td>
</tr>
<tr>
<td>Medical Oncology</td>
<td>22</td>
<td>14</td>
</tr>
<tr>
<td>Neurology</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Orthopaedics</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>Perinatal Mental Health</td>
<td>7</td>
<td>18</td>
</tr>
<tr>
<td>Radiology</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Renal</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory Medicine</td>
<td>23</td>
<td>4</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>21</td>
<td>30</td>
</tr>
<tr>
<td>Urology</td>
<td>6</td>
<td>16</td>
</tr>
<tr>
<td><strong>Totals FSFHG</strong></td>
<td><strong>227</strong></td>
<td><strong>351</strong></td>
</tr>
</tbody>
</table>

**Rockingham Peel Group (RkPG)**

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaesthetics</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Diabetes and Endocrinology</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Emergency Department</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Intensive Care Unit</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Mental Health</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Orthopaedics</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Totals RkPG</strong></td>
<td><strong>15</strong></td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>

**Totals FSFHG and RkPG**

<table>
<thead>
<tr>
<th></th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Totals FSFHG and RkPG</strong></td>
<td><strong>242</strong></td>
<td><strong>353</strong></td>
</tr>
</tbody>
</table>

*The specialty/department/service name is hyperlinked to its relevant section within the document.*
Research environment

During the last few years, the research environment within SMHS has experienced several large scale changes, and some exciting new developments to enable research activities and empower researchers:

- **Research Transition Project 2014**: research projects transitioned from Royal Perth Hospital (RPH) and FH to FSH during commissioning in 2015. 834 projects were identified in the transition tracker; 298 of which were flagged for transition to FSH.

- **Establishment of SMHS Research Ethics and Governance (REG) Unit 2016**: the Southern Integrated Research Organisation (SIRO) established in 2014, transitioned to the SMHS REG Unit.

- **The South East Transition (SET) project 2016**: this project reduced SMHS hospitals and health services from eight to five. RPH, Bentley Hospital and Armadale Kelmscott Memorial Hospital moved from SMHS to become part of the newly formed East Metropolitan Health Service (EMHS). RPH was previously a major research facility within SMHS.

- **Spinnaker Health Research Foundation 2016**: Spinnaker became the research foundation for FSH, FH and Southern Health: previously the Warren Jones Foundation. Spinnaker supports research in the form of grants and scholarships.

- **Establishment of the WA Health Translation Network (WAHTN) 2016**: WAHTN is an umbrella organisation bringing together all the major health research sectors in WA. Their role is to enable the health research translation enterprise to operate more effectively and respond to the needs of the WA Health system. WAHTN currently receives funding from the WA Department of Health to support key research initiatives contained within its strategic and operational plan.

- **Research Governance Service (RGS) 2016**: RGS is the WA Health Information Technology platform that manages all Ethics & Governance submissions and approvals across WA Health. Implementation of this system enabled WA Health to qualify for the National Mutual Acceptance Scheme in 2017.

- **Internal communication**: three different intranet sites existed in SMHS for research information and contacts. In August 2017, they were amalgamated into one central repository, which can be accessed by going to the ‘Conducting Research with SMHS’ page for further research related information.

---

3 [https://www.spinnakerhealth.org.au/](https://www.spinnakerhealth.org.au/)
Overview of SMHS research activity

Ethics approvals, governance approvals and project closure activity data for each calendar year is provided in the tables below.

### 2015 Research activity

<table>
<thead>
<tr>
<th>Dates</th>
<th>Activity</th>
<th>SMHS HREC</th>
<th>RPH HREC</th>
<th>Non-SMHS</th>
<th>2015 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Jan 2015</td>
<td>Ethics Approvals</td>
<td>103</td>
<td>74</td>
<td>13</td>
<td>190</td>
</tr>
<tr>
<td>31 Dec 2015</td>
<td>Governance Approvals</td>
<td>8</td>
<td>1</td>
<td>253</td>
<td>369</td>
</tr>
<tr>
<td>01 Jan 2015</td>
<td>Project Closure (Ethics)</td>
<td>54</td>
<td>17</td>
<td></td>
<td>71</td>
</tr>
</tbody>
</table>

*Armadale Health Service
**Bentley Health Service
*** This figure in governance is inflated due to the migration of research projects from FH to FSH during commissioning of FSH.

### 2016 Research activity

<table>
<thead>
<tr>
<th>Dates</th>
<th>Activity</th>
<th>SMHS HREC</th>
<th>RPH HREC</th>
<th>Non-SMHS</th>
<th>Total</th>
<th>2016 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Jan 2016</td>
<td>Ethics Approvals</td>
<td>42</td>
<td>48</td>
<td>6</td>
<td>96</td>
<td>205</td>
</tr>
<tr>
<td>30 Jun 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01 Jul 2016</td>
<td>Ethics Approvals</td>
<td>70</td>
<td>n/a</td>
<td>39</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>31 Dec 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dates</th>
<th>Activity</th>
<th>AHS</th>
<th>BHS</th>
<th>FSH</th>
<th>FH</th>
<th>RGH</th>
<th>RPH</th>
<th>Total</th>
<th>2016 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Jan 2016</td>
<td>Governance Approvals</td>
<td>4</td>
<td>2</td>
<td>61</td>
<td>12</td>
<td>0</td>
<td>33</td>
<td>112</td>
<td>211</td>
</tr>
<tr>
<td>30 Jun 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01 Jul 2016</td>
<td>Governance Approvals</td>
<td>n/a</td>
<td>n/a</td>
<td>79</td>
<td>10</td>
<td>10</td>
<td>n/a</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>31 Dec 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dates</th>
<th>Activity</th>
<th>SMHS HREC</th>
<th>RPH HREC</th>
<th>Total</th>
<th>2016 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Jan 2016</td>
<td>Project Closure (Ethics)</td>
<td>17</td>
<td>23</td>
<td>40</td>
<td>44</td>
</tr>
<tr>
<td>30 Jun 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01 Jul 2016</td>
<td>Project Closure (Ethics)</td>
<td>4</td>
<td>n/a</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>31 Dec 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Note that the 2016 data is represented in two distinct date ranges. Jan–Jun is prior to the migration of a number of sites (most notable RPH), to the newly formed East Metropolitan Health Service. July–December is the period after this migration.

Refer to [Appendix 2](#) for further details of the data source and parameters used for this activity report.
Research translation

SMHS researchers have changed local, national and international practice and policy, and/or directly improved patient quality and safety of care in many different ways through their research projects, and through collaboration with other research teams. Below are some examples of research translation, sourced from the achievements section of the original submissions received from the researchers:

- **Burns service:** the burns team have demonstrated the translation of research to the bedside with multiple research projects such as cell base therapies and exercise prescription; to widespread community education on the benefits of 20 minutes cooling with water as first aid for burns.

- **Emergency Departments:** the 2015 study results of the Australian Snakebite Project, which was a multi-centre study, confirmed appropriate antivenom dosing for Australian snakebite and also defined the role of Fresh Frozen Plasma (FFP) in reversing venom-induced consumption coagulopathy. A new protocol was implemented in 2016.

- **Diabetes and Endocrinology:** Dr Bu Yeap developed a national position statement on the management of men with androgen deficiency which will guide patient management to improve their clinical outcomes.

- **Gastroenterology:** high impact publications of original research in the top two ranked liver journals, including one with an editorial and international press release by the journal. Also, an evaluation was completed of the nationally implemented, locally designed Australian Red Cross Blood Service Hereditary Haemochromatosis web-based referral program, indicating substantial national resource and financial savings.

- **Neurology:** Dr Neha Khade’s project on the RACE score was vital for the establishment of the statewide ambulance bypass for hyperacute stroke and thrombectomy.

- **Neurology:** Dr Merrilee Needham is establishing a national registry for myositis patients, and is driving a translational research programme partnered with Murdoch University and Notre Dame University to investigate the immunopathogenesis of Inclusion Body Myositis and other forms of myositis.

- **Respiratory:** Dr Li Ping Chung completed a literature review and FSH internal audit of prophylactic use of antibiotics for non-Cystic Fibrosis (CF) bronchiectasis. This has resulted in the establishment and implementation of the “Guidelines for Antibiotic Prophylaxis Use in Non-CF, Non-Transplant Bronchiectasis”, which is now endorsed as FSFHG hospital wide policy.

- **Urology:** development of a cystectomy clinical outcome database (via REDCAP) at FSH in conjunction with the Australian & New Zealand Urogenital & Prostate Cancer (ANZUP) trials group, with planned national expansion.

The following sections of the report contain a synopsis of the research projects, publications and grants/funding by group (FSFHG or RkPG) and by specialty / department / service within SMHS. To provide consistency, submissions from the researchers have been documented using a standard format, and collated by specialty, department or service rather than individually based.
Fiona Stanley
Fremantle Hospitals Group
Allied Health

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audiology</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Clinical Psychology</td>
<td>*2</td>
<td>*0</td>
</tr>
<tr>
<td>Exercise Physiology</td>
<td>*0</td>
<td>*0</td>
</tr>
<tr>
<td>Occupational Therapy</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Physiotherapy</td>
<td>1</td>
<td>*8</td>
</tr>
<tr>
<td>Podiatry / MDFUC</td>
<td>*0</td>
<td>0</td>
</tr>
<tr>
<td>Speech Pathology</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Social Work</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>6</strong></td>
<td><strong>20</strong></td>
</tr>
</tbody>
</table>

*Please note that further Allied Health projects and / or publications are documented within other specialty/department sub-sections, as they are collaborative or multi-disciplinary in nature.

Audiology

Publications: 9 (3 in 2016; 6 in 2015)

2016 (3)


2015 (6)


Acharya AN, Coates H, Távora-Vieira D, Rajan GP. (2015). *A pilot study investigation basic fibroblast growth factor for the repair of chronic tympanic membrane perforations*


Clinical Psychology

Projects: (2)

A randomised controlled trial (RCT) of a psychological intervention (Conquer Fear) to reduce clinical levels of fear of cancer recurrence in breast, colorectal and melanoma cancer survivors (39123)

Phyllis Butow, Belinda Thewes, Louise Sharpe, Jane Turner, Jemma Gilchrist, Afaf Girgis, Allan Smith, Joanna Fardell, Stephanie Tesson, Jane Beith, Rebecca Asher, Members of the Conquer Fear Authorship Group.

Please refer to Endocrinology and Diabetes section for further research activities – Clinical Psychologist M. Burkhardt.

Exercise Physiology

Projects: refer to Cardiology section for five collaborative projects – Professional Lead Exercise Physiology A. Maiorana.

Publications: refer to Cardiology section for seven collaborative research articles – Professional Lead Exercise Physiology A. Maiorana.

Grants/funding: 2016

National Heart Foundation – Vanguard Grant. Refer to Cardiology section – Professional Lead Exercise Physiology A. Maiorana.

Occupational Therapy

Projects: (1)

Sue Winnall, Amy Oliver, Bec Kevill, Laura Ensor, Lauren Hart, Lezahn Rens, Bethany Williams. Phase 2 of the “The Development of an Occupational Therapy Pathway for Mild Traumatic Brain Injury”.

Publications: (1)

J W Middleton; L Piccenna; R Lindsay Gruen; S Williams; G Creasey; S Dunlop; D Brown; P E Batchelor; D J Berlowitz; S Coates; J A Dunn; J B Furness; M P Galea; T Geraghty; B K Kwon; S Urquhart; D Yates; P Bragge. Developing a spinal cord injury research strategy using a structured process of evidence review and stakeholder dialogue. Part III: outcomes. Spinal Cord, 2015.

Physiotherapy

Projects: (1)

Alisha Anderson, Jo Jenkin, Andrea King in conjunction with Curtin University Physiotherapy. “Reliability and Validity of the Four Point Pusher Scale: An Assessment Tool for Measuring Lateropulsion and Pusher Behaviour in Adults Following Stroke”.
Publications: 8 in 2016

2016: (8)


Refer to Burns section for collaborative research articles – Senior Physiotherapists: P. Gittings and D. Edgar.

2015

Refer to Emergency Medicine section – Use of a risk nomogram to predict emergency department reattendance in older people after discharge: a validation study.

Refer to Burns section for collaborative research articles – Senior Physiotherapist D. Edgar.

Podiatry/MDFUC

Refer to Endocrinology and Diabetes section – Observational study of admissions to the inpatient Multidisciplinary Diabetic Foot Unit at Fiona Stanley Hospital: experiences from the first year of operation. Lydia Lamb, Dipen Sankhesara, Tina Dilevska, Erica Ryan, Ashley Makepeace, Gerry Fegan, Carsten Ritter, Paul Norman, Laurens Manning, Emma J Hamilton.

Speech Pathology

Projects: (1)

Missing voices: Communication difficulties after stroke and traumatic brain injury in Indigenous Australians. Led by Professor Elizabeth Armstrong (Edith Cowan University) and a team of Aboriginal and non-Aboriginal researchers the Missing Voices project explored the extent and impact of acquired communication disorders (ACD) after stroke and traumatic brain injury (TBI) in Aboriginal communities across WA. Multi-centred, mixed methodology project.

Publications: 2 (1 in 2016 and 1 in 2015)

2016 (1)

2015 (1)

Grants/funding:
NHMRC – Missing Voices project.

Social Work
Projects: (1)
Travelling for Treatment of a burn injury: the experiences of Aboriginal women who relocate to the State Adult Burns Unit at Fiona Stanley Hospital. Supported by Notre Dame University.
Anaesthetics

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaesthetics</td>
<td>9</td>
<td>11</td>
</tr>
</tbody>
</table>

Projects: (9)

**PADDI** – investigating the impact of dexamethasone on surgical site infection. E O’L; Al-A, operations and steering committee.

**BALANCED** – ANZCA clinical trials group, NHMRC funded study investigating the link between depth of anaesthesia and post-operative outcome.

**IronNOF** – investigator initiated, SHRAC funded study of the association between intravenous iron infusion peri-operatively and transfusion outcomes. E O’L PI.

**PIPE** – assessment of coagulation in pre-eclampsia. Investigator initiated, Hamish Mace PI.

**Posterior cutaneous nerve of thigh mapping** – Dr Kris Owen PI, investigator initiated.

**Does the genetic knockdown of sodium channel Nav1.7 expression switch off chronic neuropathic pain?** Investigator initiated, Dr Michal Luniewski

**ARC** – airway rescue course. Investigator initiated, high fidelity simulation and research of ‘Can’t Intubate/Can’t Oxygenate’ scenarios in anaesthetised pig model run in conjunction with Murdoch Vet school. Multiple investigators.

**Hepcidin and bone marrow Iron in fractured neck of femur patients.** Investigator initiated, ANZCA funded. E O’L PI

**Applying the cell-based coagulation model in the management of critical bleeding,** SHRAC funded. Dr Warren Pavey PI.

Publications: 11 (5 in 2016; 6 in 2015)

**2016: (5)**

R Ramadas, S Hendel, MacKillop, Civilian aeromedical retrievals (the Australian experience) BJA Education, Volume 16, Issue 6, 1 June 2016, Pages 186–190


Corcoran TB, Mas E, Barden AE, Roberts LJ, 2nd, Mori TA, O’Loughlin E. Controlled moderate hypovolaemia in healthy volunteers is not associated with the development of oxidative stress assessed by plasma F2-isoprostanes and isofurans. 2016; 124: 34–8.


**Grants/funding:**

2016 RAINE foundation – Clinical Research Fellowship, Clinical Associate Professor Ed O’Loughlin – PADDI and IronNOF projects

PADDI – NHMRC funded study.
Projects: (17)

Current activities cover a wide spectrum of practice from Safety and Quality to major programs based at FSH including:

- the role of early laser in scar outcome
- the use of bioimpedence in measurement of oedema post burn injury
- collagen turnover in established scarring using heavy water
- post traumatic growth and impact on outcome post burn injury
- measurement of stress and activity to drive improved outcomes
- data analytics in understanding the drivers to excellence in clinical care
- IBM Watson Drug Discovery exploring the links between burn injury and chronic disease such as cancer DM CVD
- a population data linkage program comparing burn and non-burn trauma
- collaboration with ICU in the recently commenced Probiotics trial
- link with burns research in UWA collaborating with biomedical engineering
- collaboration with nano chemistry on a range of cell performance in scaffolds
- understanding the mechanisms of fibrosis comparing skin with other tissues
- involved in a NHMRC partnership grant exploring LOX inhibitors in scarring
- the impact of surgical planning on injury outcome
- burn injury of the lower limb in diabetic patients and the role of hyperbaric oxygen
- collaboration with the CRC in special imaging for burn injury assessment
- RCT exploring the use of anti-inflammatory drug therapy in acute burn injury.
Publications:  80 (43 in 2016 and 37 in 2015)

2016 (43)

Advances in Isolation and Expansion of Human Cells for Clinical Applications.  
F Wood, Skin Tissue Engineering and Regenerative Medicine, pp.299–315, Dec 2016.

Demonstration of the test-retest reliability and sensitivity of the Lower Limb Functional Index-10 as a measure of functional recovery post burn injury: a cross-sectional repeated measures study design.  

The impact of non-severe burn injury on cardiac function and long-term cardiovascular pathology.  
Scientific Reports, Oct 2016.

Post-traumatic growth after burn in adults: An integrative literature review.  
L Martin, M Byrnes, S McGarry, F Wood.  

Burn leads to long-term elevated admissions to hospital for gastrointestinal disease in a West Australian population based study.  

Grip and Muscle Strength Dynamometry are reliable and valid in patients with unhealed minor burn wounds.  

Respiratory Morbidity After Childhood Burns: A 10 year follow-up study.  
Pediatrics, Sep 2016.

Burn injury and long-term nervous system morbidity: A population-based cohort study.  

Social challenges of visible scarring after severe burn injury: A qualitative analysis.  
L Martin, M Byrnes, S McGarry, F Wood.  
Burns, Aug 2016.

Patient opinion of scarring is multidimensional: An investigation of the POSAS with confirmatory factor analysis.  
H Dejong, M Phillips, D Edgar, F Wood.  

Telehealth for paediatric burn patients in rural areas: A retrospective audit of activity and cost savings.  
T McWilliams, J Hendricks, D Twigg, F Wood, M Giles.  

ISBI Practice Guidelines for Burn Care.  
Burns, Aug 2016.

The effectiveness of session rating of perceived exertion to monitor resistance training load in acute burns patients.  
T Grisbrook, P Gittings, F Wood and D Edgar.  

Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Control Trial.  

Effects of Paediatric Burns on Gastrointestinal Diseases: A Population-Based Study.  
Journal of burn care &


Predictors of moderate to severe fatigue 12 months following admission to hospital for burn: Results from the Burns Registry of Australia and New Zealand (BRANZ) Long Term Outcomes project. B Gabbe, H Cleland, D Watterton, R Schrale, S McRae, C Parker, S Taggart, D Edgar. Burns. Oct 2016.


2015 (37)


Interpretation of the DermaLab Combo® pigmentation and vascularity measurements in burn scar assessment:


Advances in isolation and expansion of human cells for clinical applications. Wood, F. Skin Tissue Engineering and Regeneration Medicine, Albanna, Ch 15.


The Brief Fatigue Inventory is reliable and valid for the burn patient cohort. Toh, C; Li, M; Finlay, V; Jackson, T; Burrows, S; Wood, F; Edgar, E. Burns, August 2015, Vol 41(5), pp 990–997.


Grants/funding:

Various grants/funding received.
At the end of 2016, we have 26 clinical trials (including 4 TAVI) underway, with a total of 234 patients who are in active follow up.
Projects in close out: (3)


RELAX 2: A multicenter, randomized, double-blind, placebo controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients. Kaitlyn Lam.

EVOLVE: A Prospective Randomized Multicenter Single-blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System for the Treatment of a De Novo Atherosclerotic Lesion.

Cardiology/Allied Health collaboration projects: (5)

Maiorana A, Dorje T. TEXTMEDS – TEXT messages to improve MEDication adherence and secondary prevention. (Investigator initiated).

Maiorana A, Chen S. A randomised controlled trial of nurse-supported telehealth for people with heart conditions. (Investigator initiated).

Maiorana A, Dembo L. The impact of left ventricular assist device implantation on physical activity levels in patients with advanced chronic heart failure. (Investigator initiated).


Publications: 14 (8 in 2016 and 6 in 2015)

2016: (8)


Ihdayhid AR, Asrar Ul Haq M, Dembo L and Yong G. Simultaneous Coronary and Pulmonary Angiography to Diagnose Critical Left Main Coronary Artery Stenosis Secondary to Dilated Pulmonary Artery JACC Cardiovasc Interv 2016;9:1193–4


2015: (6)


Grants/funding:

# Emergency Medicine

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Medicine</td>
<td>4</td>
<td>25</td>
</tr>
</tbody>
</table>

### Projects: (4)

**The NEED study**: comparing discharge risk assessment tools for older ED patients.
- **Single centre FSH investigator research.** Principal Investigator (PI): Arendts G.

**FEM FIG BUG**: RCT of ultrasound guided femoral nerve and fascia iliaca blocks for hip fracture.
- **Single centre FSH investigator research.** PI: Watson P.

**REFRESH**: RCT of standard versus restricted fluid volume resuscitation in sepsis.
- **Multicentre investigator research.** PI: Arendts G.

**ASP**: study of snake bite epidemiology and antivenom use.
- **Multicentre investigator research.** PI: Nagree Y.

### Publications: 25 (15 in 2016; 10 in 2015)

**2016 (15)**


Fry M, Chenoweth L, Arendts G. **Assessment and management of acute pain in the older person with cognitive impairment: A qualitative study.** Int Emerg Nurs 2016; 24:54–60.


Francis A et al. **Neutrophil activation during anaphylaxis.** Australasian Society of Clinical Immunology and Allergy 27th Annual


2015 (10)


Schnitker LM, Martin-Khan M, Burkett E, Brand CA, Beattie ERA, Jones RN, Gray LC


**Grants/funding:**

**2016:**

Schnittker L, Beattie E, Arendts G, Carpenter CR. **The development and evaluation of an educational program for the care of older people with dementia in emergency departments.** Alzheimer’s Australia Dementia Research Foundation 2016–17.


Arendts G. **MHRIF Funding Round 19. 2016.**

**2015:**

Arendts G. **A Randomised Trial of Post Discharge Intervention in High Risk Older People Discharged from the Emergency Department.** WA Department of Health Merit Award Projects. 2015.
Endocrinology and Diabetes

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrinology and Diabetes</td>
<td>15</td>
<td>64</td>
</tr>
</tbody>
</table>

Projects (15)

Current research projects (7):

Bu Yeap and collaborators: hormones and men’s health (epidemiological studies).

Bu Yeap and collaborators: testosterone to prevent diabetes in men at high risk (RCT).

Bu Yeap and collaborators: testosterone and exercise to improve vascular health in men (RCT).

Emma Hamilton. Audit of Multidisciplinary Diabetic Foot Unit (MDFU) services at Fremantle and Fiona Stanley Hospitals.

Emma Hamilton. Do patients with Foot Ulceration and Type 2 Diabetes have Cognitive Impairment and lower levels of Self-care Behaviour?

Emma Hamilton. 10 year longitudinal study of bone mineral density in patients with type 1 diabetes.

Melanie Burkhardt, Gerry Fegan and Bu Yeap: Improving diabetes self-care in high risk patients.


Quality improvement activities (8):

Melanie Burkhardt and collaborators (GEKO 8222). Enhanced Self-Care for Diabetes Group Program Evaluation.

Melanie Burkhardt and collaborators (GEKO 11165). Prevalence of body image distress, problematic eating, suboptimal self-care and glycaemic control in adults with type 1 diabetes attending a tertiary hospital outpatient setting.

Gerry Fegan and collaborators (GEKO 9935). FSH inpatient diabetes review.


Emily Gianatti and collaborators (GEKO 9049). Audit of clinical outcomes of pregnant women attending FSH with Diabetes in Pregnancy.

Gerry Fegan and collaborators (GEKO 9070). Glycaemic control amongst hospitalised geriatric patients in an acute setting.

Emily Gianatti and collaborators (GEKO 13558). Audit of use of Obstetric Blood Glucose Record and Insulin Prescription Chart.

Gerry Fegan and collaborators (GEKO 11678). Diabetes Ketoacidosis (DKA) Clinical Audit.

Publications: 64 (26 in 2016 and 38 in 2015)

2016 (26)


2015 (38)


Yeap BB, Divitini ML, Gunton JE, Olynyk JK, Beilby JP, McQuillan B, Hung J, Knuiman MW. Higher ferritin levels, but not serum iron or transferrin saturation, are associated with Type 2 diabetes mellitus in adult men and women free of genetic haemochromatosis. Clinical Endocrinology 2015; 82: 525–532.


Bruce DG, Hunter ML, Peters KE, Davis TME, WA Davis. Fear of falling is common in patients with type 2 diabetes and is associated with increased risk of falls. Age and Ageing 2015; 44:687–690.


Grants/funding:

2016:

Yeap B, MHRIF grant

Davis TME et al, Project grant 1042231. A comprehensive assessment of diabetes in the urban community of Fremantle.


Davis TME, Health Department of Western Australia. Evaluation of Diabetes Collaborative Complex Care Pilot project. 2016, 2017.

Davis TME, Bruce DG, Davis WA, Bulsara MK, Fegan PG, Finn J. Hypoglycaemia in adults with diabetes: Incidence, cost and novel preventive strategies. Fremantle Hospital Medical Research Foundation.

Davis TME, Comparability of the characteristics and outcomes of patients with type 2 diabetes recruited to the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and patients in the Fremantle Diabetes Study Phase II satisfying LEADER entry criteria. NovoNordisk Pharmaceuticals.


2015:


Yeap B, Green D and Naylor L. Heart Foundation Vanguard Grant 100578 Testosterone and Exercise: a new direction for ageing men?

Yeap B, MHRIF grant

Davis TME, Merck Sharp and Dohme Australia. Indigenous participation in the Fremantle Diabetes Study.

Davis TME et al, Project grant 1042231. A comprehensive assessment of diabetes in the urban community of Fremantle.
Gastroenterology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastroenterology</td>
<td>15</td>
<td>38</td>
</tr>
</tbody>
</table>

**Current projects: (15)**

Sirolimus and microcytic anaemia: Effect on iron utilization and inflammation as compared to calcineurin inhibitors. Investigators – Krishnan A, Olynyk J, Swaminathan S.

Principal Investigator FSH site (O.T. Ayonrinde) for “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis”

Principal Investigator FSH site (O.T. Ayonrinde) for “A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multi-Centre Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis”

Endoscopist prediction of colonoscopy findings from pre-procedure data. Is colonoscopy like a box of chocolates or can we predict what we are going to find? (O.T. Ayonrinde)

Characteristics and prediction of patients with poor bowel preparation for colonoscopy (FSH/FH) (O.T. Ayonrinde)

The impact of alcohol consumption on tolerability and efficacy of bowel preparation for colonoscopy (O.T. Ayonrinde)

AzurRx: A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy (C Pearce)

Phase 3 randomised, double-blind, double dummy, placebo-controlled, multicentre study to evaluate the efficacy (induction of remission) and safety of etrolizumab compared with adalimumab and placebo in patients with moderate to severe ulcerative colitis who are naïve to TNF inhibitors.

Phase 3 double blind, placebo-controlled, multicentre study of the efficacy and safety of etrolizumab during induction and maintenance in patients with moderate to severe active ulcerative colitis who are refractory to or intolerant of TNF inhibitors.

A phase 3 randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of etrolizumab as an induction and maintenance treatment for patients with moderately to severely active Crohn’s disease.

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy.

A phase 3 randomised, double blind, placebo- controlled, multicentre study to investigate the efficacy and safety of Mongerson (GED 0301) for the treatment of subjects with active Crohn’s disease.

Factors contributing to early postoperative endoscopic recurrence in Crohn’s disease.

Predictors of recurrent medical admissions in IBD patients at a tertiary hospital.
Prospective open label cohort study of biosimilar infliximab vs originator infliximab (“SAME” study).

**Publications:** 38 (19 in 2016; 19 in 2015)

**2016 (19)**


Subramaniam K, Spilsbury K, Aynrinde OT, Latchmiah F, Mukhtar SA, Semmens JB, Leahy MF, Olynyk JK. Red blood cell transfusion is associated with further bleeding and fresh-frozen plasma with mortality in nonvariceal


2015 (19)


Grants/funding:


Role of non-transferrin bound iron in iron overload disease. Investigators Deborah Trinder, John Olynyk, Anita Chua. NHMRC Project Grant.
Cellular cross-talk between liver progenitor cells and hepatic stellate cells is required for hepatic fibrogenesis. Grant Ramm, John Olynyk, Janina Tirnitz-Parker. NHMRC Project Grant.

Understanding and applying white blood cell-mediated effects on liver stem cells to treat liver disease. Investigators George Yeoh, John Olynyk, Caryn Elsegood, Ruth Ganss. NHMRC Project Grant.

2016 – Medical Health and Research Infrastructure Fund. 2016 Round 20. Investigator John Olynyk


Inflammatory Bowel Disease Service:

- Research Fellow 0.5 FTE grant – Research Fellowship from WA Department of Health
- ABBVIE benevolent grant for research seed funding.

Haematology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haematology</td>
<td>23</td>
<td>0</td>
</tr>
</tbody>
</table>

Commercial projects: (11)

- ENESTswift: A multicenter, single arm study to assess efficacy and safety of nilotinib 300mg BD in patients with Philadelphia positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) who are intolerant to prior tyrosine kinase inhibitors (TKIs)
- CHRONOS-4 A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (NHHL)
- A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors
- A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 with and without ATRA (Tretinoin) in Patients with Advanced Myeloid Malignancies
- A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma
- A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)
- A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma
- A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma.
- Acrave Hemophilia a Outcome Database (AHEAD). A phase 3 prospective, multicenter study to evaluate efficacy and safety of rVWF with or without Acrave in elective surgical procedures in subjects with severe von Willebrand disease
- A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with haemophilia (A or B) and inhibitors A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A.

Investigator Initiated projects : (12)
- Mesenchymal stromal cell therapy for acute graft versus host disease
- Aplastic Anaemia (AA) Registry
- NHL29: A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL
- Investigation of endothelial toxicity after allogeneic haematopoietic stem cell transplantation
- Lymphoma and Related Diseases Registry
- Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry
- A Phase II Trial of an intensive Pediatric Protocol incorporating Post induction stratification based on minimal residual disease levels for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years with newly diagnosed acute lymphoblastic leukaemia (ALL)
- A Phase III randomized study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
- Outcomes of patients treated for T-Cell Lymphoma in Metropolitan Tertiary Hospitals, Western Australia 2005-2014
- Prospective Study Assessing the Incidence of Hypokalaemia in Haematological Patients Receiving Posaconazole Anti-Fungal Prophylaxis as Part of their Standard Treatment Regimen.
- Australian Bleeding Disorders Registry (ABDR)
- Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis TWISTER.

Publications
List not available at time of reporting.

Grants/funding:
Nil
Intensive Care Unit (ICU)

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive Care Unit</td>
<td>6</td>
<td>13</td>
</tr>
</tbody>
</table>

Projects: (6)

**ADRENAL** – Investigator-initiated multicentre RCT of corticosteroids for septic shock. NHMRC funded. Site investigator Dr Adrian Regli.

**ICU-ROX** – Investigator-initiated multicentre RCT of avoidance of hyperoxia in mechanically ventilated patients admitted to the ICU. HRC NZ funded. Study management committee Dr Ed Litton.

**PEPTIC** – Investigator-initiated multicentre cluster crossover RCT of proton pump inhibitor vs ranitidine for patients receiving mechanical ventilation in the ICU. HRC NZ funded. Study management committee Dr Ed Litton.

**PINBALL** – Investigator-initiated multicentre RCT of prophylactic intraaortic balloon pump in high risk cardiac surgery. Funded by Heart Foundation Grant. Chief Investigator Dr Ed Litton.

**TARGET** – Investigator-initiated multicentre RCT of calorie goal for patients admitted to the ICU who require enteral nutrition. NHMRC funded. Site investigator Dr Bart De Keulenaer.

**TRANSFUSE** – Investigator-initiated multicentre RCT of standard or freshest available packed red blood cell transfusion. NHMRC funded. Site Investigator Dr Chris Allan.

Publications: 13 (8 in 2016; 5 in 2015)

**2016 (8)**


Surgery 2016.


2015 (5)


Grants/funding:

ROCIT RCT – 2016 RTP DoH WA. Dr Ed Litton, CPI, Multicentre RCT of probiotic therapy to reduce nosocomial infection and shorten length of stay in critically ill patients admitted to the ICU.

Medical Oncology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Oncology</td>
<td>22</td>
<td>14</td>
</tr>
</tbody>
</table>

Projects:

Clinical Trials Unit information: 22 sponsored projects (14 in 2016; 8 in 2015)

2016 (14)

Breast:

A5481037 – A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, HER2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate. Protocol A5481037

ELIMINATE - Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to downstage large oestrogen receptor positive breast cancer. Protocol ANZ 1401

EMBRACA - A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease. Protocol 673–301

Colorectal/Gastric:

JAVELIN Gastric 300 – A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma. Protocol EMR100070–008

Lung:

JAVELIN Lung 100 – A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non-small-cell lung cancer. Protocol EMR 100070–005

BR.31 – A Phase III Prospective Double Blind Placebo Controlled Randomised Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer. Protocol No: BR.31

CheckMate 227 – An Open-Label, Randomized Phase 3 Trial of Nivolumab versus platinum doublet chemotherapy and Nivolumab plus Ipilimumab versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC). Protocol BMS No. CA209–227

CheckMate 331 – An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy. Protocol No: CA209–331

Urothelial:

BL.12 – A multicentre randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum-containing regimen. (EC Reg 2014–151 Protocol No: NCIC CTG BL.12)

PHASE 1 metastatic or locally advanced solid tumours:

TRAP – A Phase I, open-label, multiple-ascending dose trial to investigate the safety,
tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumours and expansion to selected indications. Protocol No. EMR 200647–001

**Melanoma:**

**CheckMate 401** – A Phase 3b Clinical Trial of Nivolumab (BMS–936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma. Protocol CA209–401.

**MASTERKEY-265** - A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma. Amgen Protocol No. 20110265

**TACTI-mel (Two ACTive Immunotherapeutics in Melanoma):** A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab. Protocol No. IMP321–P012.

2015 (8)

**Prostate:**


**Renal:**

**CheckMate 214** – A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 214). Protocol No: BMS CA209–214.

**Colorectal/Gastric:**

**BRIGHTER** – A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BB1608 plus weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma. Protocol No: BB1608–336

**Breast:**

**PENELOPEB** – Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy. Protocol GBG-78 – BIG 1–13 – NSABP – B–54–I

**Neuroendocrine:**

**CONTROL NETS** – Two non-comparative parallel group phase II randomised open label trials of Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study (EC Reg 2015–035 Protocol No: AGITG CTC0120/AG0114NET

**Melanoma:**


**Lung:**

**ARCTIC** – A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of
Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements. Protocol No: AstraZeneca D4191C00004


**Publications: 14 (7 in 2016; 7 in 2015)**

**2016 (7)**


How Australians Die: Cause 2 – cancers. Slevin, Terry; Redfern, Andrew. The Conversation. 7th June 2016.

Redfern, Andrew; Burslem, Katie; Woodward, Natasha; Beith, Jane; McCarthy, Nicole; De Boer, Richard; Bell, Richard. Hormone receptor positive, HER2 negative metastatic breast cancer: a systematic review of the current treatment landscape. Asia Pac J Clin Oncol. 2016 Mar; 12 Suppl 1:3–18.


**2015 (7)**


Cursons J, Leuchowius KJ, Waltham M, Tomascovik-Crook E, Foroutan M, Bracken C, Goodall G, Redfern A, Crampin EJ, Street I, Davis MJ and Thompson EW. Stimulus-dependent differences in signalling regulate


Grants/funding:

2016

NHMRC Project Grant APP1108711 – A Redfern CIB. Characterization of a new subtype of aggressive breast cancer.

NHMRC Project Grant APP1121199 – A Redfern CIB. Activation of BMP4 signalling to inhibit breast cancer metastasis.

CCWA Project Grant – A Redfern. CIC. Preventing breast cancer from spreading by stopping immune cell movement.

MRF Grant (RPH) – A Redfern. CIB. Novel drivers of progression and treatment resistance in breast cancer.

NBCF Innovator Grant – A Redfern. AI. Modulating gene expression in breast cancer by targeted epigenome engineering of quadruplex DNA.

CCWA Project Grant – A Redfern. AI. A novel strategy to kill triple negative breast cancers.

Cancer Council WA Project Grant – AI. Control of osteosarcoma cell migration and invasion by the scaffold protein afap111.

2015

NHMRC Project Grant APP1108711. A Redfern Al. Nuclear receptors and triple negative breast cancer.

Cancer Council WA Project Grant – A Redfern CIB. Discovery & characterisation of a cancer driver in a new subtype of aggressive breast cancer.

WA CPCN Special Purposes Grant – A Redfern. CIA. Role of Breast Tumour Biology in Adverse Outcomes for Indigenous Women.

WA CPCN Special Purposes Grant – A Redfern. CIB. Development of an Evidence-Based Breast Cancer Follow-up Program.
# Neurology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurology</td>
<td>11</td>
<td>11</td>
</tr>
</tbody>
</table>

## Projects: (11)

### Stroke Trials (3)

**Affinity** – Supplier (AMNEAL pty ltd). The assessment of Fluoxetine in stroke recovery.

**Navigate Esus** – (Bayer). Secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS).

**Verse** – Very early rehabilitation in aphasia following stroke.

### Other studies: (8)

**Dysphagia Study** investigating the utility of EMST devise in improving dysphagia in IBM patients

**Completion of BYM338** (performed at Perron by Prof M Needham)

**Databasing Myositis patients** (ongoing)

**Biobanking Myositis patients** (ongoing)

**Basic Science studies investigating the immunopathogenesis of myositis** (ongoing)

**Investigating the genetic risk factors for MND**

**Contributing to the Australian Motor Neuron Disease Registry**

Two MS clinical trials: PHOCIS and PreVANS.

## Publications: 11 in 2016

### 2016 (11)


Grants/funding:

Myositis Association Grant 2015 for immunopathogenesis and antibody studies

Murdoch University: funded a post-doc position for Prof Needham for 2 years.
Orthopaedics

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orthopaedics</td>
<td>9</td>
<td>11</td>
</tr>
</tbody>
</table>

**Projects: (9)**

**Absolut Hip.** Clinical & Radiological Outcome using the Absolut femoral prosthesis and the Global cup system (AGC-COP13S). Yates (PI), Khorshid, Fellow, Wall, Bucher, Prosser. Sites: FH and RGH

**Accolade II Hip.** A prospective multi-centre randomised comparative study of implant fit, clinical outcomes and satisfaction with the Stryker Accolade II hip stem compared to the Corail him Stem. Khorshid (PI), Yates, Prosser, Wall, Fellow. Sites: FH and RGH

**Saiph Knee.** Investigation into the tibial fixation of the Saiph TKR – RSA study. PY, Fellow. Site: FH

**10004 Attune Knee.** Prospective, single arm, Attune primary total knee arthroplasty system study. PY, GP, Fellow. Sites: FH,RGH,OP,SJOG

**10003 PFC Knee.** Multi-center, non-comparative study of primary TKA functional performance. PY, GP, Fellow. Sites: FH,RGH,OP,FSH

**Legion Hinge Knee.** A prospective Multicentre study evaluating the Legion hinge knee system (Links Study). PY, GP. Sites: SJOG,FH

**Persona Knee.** Prospective Multi-centre outcomes study of Persona knee system in TKA. Okh, BR, GP, TB. Site: FH

**Rhino.** Rehabilitation of Humerus Injuries Non-operatively and their Outcomes (RHINO) Study. Chris Lim. Sites: FH / RGH

**Apex Knee-VivoFit.** Investigation into the influence of patient ambulation and components alignment on medium term patient outcomes after total knee arthroplasty (Apex Study). Okh, TB, BJ. Site: FH.

**Publications: 11 (3 in 2016; 8 in 2015)**

**2016 (3)**


**2015 (8)**


Extreme Cobalt Toxicity: Bearing the Brunt of a Failed Ceramic Liner. JBJSA 2015.


Comparison of patient outcomes in periarticular and intra-articular local


Other publications:
FSH Heralds Changes to Orthopaedics. Medical Forum March 2015.

Grants/funding:
Each project has a commercial sponsor.
RHINO Study: Spinnaker grant.

Perinatal Mental Health

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perinatal Mental Health</td>
<td>7</td>
<td>18</td>
</tr>
</tbody>
</table>

Projects: (7)

Galbally, Lewis, Spencer, Nguyen & Kristianopulos. South Metropolitan Pregnancy and Emotional Wellbeing Study. Funded by Spinnaker Anniversary Grant and Kallis PhD scholarship. UNDA PhD Student Karen Redhead. Murdoch University Honours and Masters of Clinical Psychology Students

Galbally, Lewis, van IJzendoorn, Permezel, Lappas, Saffery & Ryan. Mercy Pregnancy Emotional Wellbeing Study (HREC R08/22). Funded by a National Priority Research Grant, Beyond Blue and NHMRC Project Grant. UNDA PhD Student Dr Josephine Power, Murdoch University DPsych, Honours and Masters of Clinical Psychology Students

Galbally, Frayne, Snellen, Management and Outcomes in an antenatal clinics for women with Bipolar Affective Disorder and Schizophrenia collaborative project with King Edward Memorial Hospital (KEMH)

Galbally. Co-Chair Mental Health RIG, ORIGINS

Galbally. Co-Lead Perinatal and Life Course SIG, Raine Study

Galbally, Kristianopulos, Schutte & Lange. The development of a purpose-designed database, and to collect perinatal and neonatal data from the MBU at FSH. Funded by WA Mental Health Commission Grant

Galbally & Kristianopulos. Clinical Audit GEKO: Audit of all patients admitted to the FSH MBU from 01/08/15 to 31/07/16.

Publications: 18 (9 in 2016; 9 in 2015)

2016 (9)


Galbally, M; van IJzendoorn, M; Permezel, M; Saffery, R; Lappas, M; Ryan, J; van Rossum, E; Teti, D; Johnson A; Lewis A. Mercy Pregnancy and Emotional Wellbeing Study (MPEWS): understanding maternal mental health, fetal programming and child development. Study design and cohort profile. International Journal of Methods in Psychiatric Research. Online Ahead.


Boyce, P; Galbally, M; Gregoire, A. Pregnancy: the earliest opportunity for prevention and early intervention for mental disorders. Oxford Textbook for Public Mental Health. Accepted and In press

Lewis, A; Galbally, M. Pregnancy. The SAGE Encyclopedia of Lifespan Human Development (Bornstein). Accepted and In Press.

Galbally, M; Romans, S; Buist, A. Women’s Mental Health In: Eds Bloch et al. Foundations in Clinical Psychiatry. 4th Ed, Melbourne University, 2016.

2015 (9)


Blankley; Galbally; Snellen; Power; Lewis (2015). Borderline Personality Disorder in the Perinatal Period: Outcomes for Mothers and Infants. Australasian Psychiatry. 23, 6 688–692.


Galbally, M; Snellen, M. Mental Health Disorders During the Perinatal Period. In: Eds Permezel, Walker and Wein. Obstetrics, Gynaecology and the Newborn. 4th Ed, Elsevier. 2015


O’Hara; Dennis; McCabe; Galbally. Evidence-Based Treatments and Pathways to Care. In: Eds Milgrom J. & Gemmill A. Identifying Perinatal Depression and Anxiety: Evidence-based Practice in Screening, Psychosocial Assessment and Management. Wiley and Sons 2015

Grants/funding:

CIA Galbally 2016: Spinnaker Collaborative Partnership Grant/Fremantle Hospital Medical Research Foundation 20th Anniversary Grant. Principal Investigator Southern Metropolitan Pregnancy and Emotional Wellbeing Study.

CIA Galbally 2015 NHMRC Project Grant.

CIA. The transmission of perinatal maternal mental health to preschool emotional disorders: Examining pathways and intervention points in the MPEWS study APP1106823.

CIA Kristinopulos. WA Mental Health Commission Grant: MBU database.

Kallis PhD Scholarship: Karen Redhead Murdoch University: 2 year Post-Doctoral Research Fellow.

Radiology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiology</td>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

Projects: (2)


Computed tomography pulmonary angiography referred from ED at FSH: An audit to determine if the test is being utilized optimally in the investigation of suspected pulmonary embolism.

Publications: (2)


Grants/funding:

Nil

Renal

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal</td>
<td>18</td>
<td>0</td>
</tr>
</tbody>
</table>

Projects: 18 in total

Projects with multiple sponsors (9)

aHUS Registry – An Observational, Non-Interventional, Multi-Centre, Multi-National Study of Patients with Atypical Haemolytic-Uraemic Syndrome, Site investigator: Abu Abraham

EVIDENCE – EValuation of Potential PredIctors of Disease ProgrEsson in Patients with aHUS Including GeNetiCs, BiomarkErs, and Treatment, Site investigator: Abu Abraham

PEXIVAS – Plasma exchange and steroid dosing in the treatment of anti-neutrophil
cytoplasm antibody (ANCA) associated vasculitis: an international randomized controlled trial, Site investigator: Abu Abraham

**PRO2TECT – CORRECTION**, Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease, (Sponsor Funded) Site investigator: Ashley Irish

**PRO2TECT – CONVERSION**, Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease, Site investigator: Ashley Irish

A non-interventional, open label, prospective, long term national registry for patients with lupus nephritis on immunosuppressant therapy. **The Lupus Nephritis Australian Registry – LUNAR**, Site investigator: Ashley Irish

**TRANSFORM** – A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation-Advancing renal TRANSplant efFicacy and safety Outcomes with an eveRolimus-based regiMen, (Sponsor Funded) Site investigator: Ashley Irish

**CMV** – Renal transplants, Site investigator: Suda Swaminathan.


**Investigator Initiated projects: 9 (some with partial sponsorship or grants)**

The **CKD-FIX Study**: an investigator-initiated, multicentre, prospective, randomised, double-blind, placebo-controlled; parallel-arm trial testing the hypothesis that compared to placebo, uric acid-lowering therapy with xanthine oxidase will significantly slow the progression of kidney failure in patients with moderate to severe chronic kidney disease. Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase (Partially Sponsor Funded) Site investigator: Ashley Irish

**A Pilot Study to Evaluate the Potential of Mesenchymal Stromal Cells** as adjunctive treatment of Humoral and Cellular Renal Graft Rejection after Renal Transplantation from Living Donors, Site investigator: Ashley Irish

A phase 1 study to determine safety and efficacy of infusion of mesenchymal stromal cells in patients undergoing deceased donor renal transplantation in prevention of the ischaemia-reperfusion injury, Site investigator: Ashley Irish

**HLA Study** – The aim of our research is to store DNA from each transplant recipient and a sample of serum to allow us to test for existing and new factors that impact on the kidney and patient outcomes. If we find that the level or type of HLA antibody or other immunological or non-immunological mechanisms of kidney injury after the transplantation are important, we hope to further examine the genes which may influence this incompatibility between donor and recipient and therefore kidney transplant outcome, Site investigator: Ashley Irish

**HLA Antibody** – Hep B Vaccine Pilot Study. In this study we wish to examine whether Hepatitis vaccination can induce an antibody response against not only the Hepatitis B vaccine, but more broadly against HLA antigens and if so is this response transient or enduring, and is it predicted by the strength of Hepatitis B response (low versus high responders). Site investigators: Ashley Irish, Orla O’Brien
**Effect of parathyroidectomy on arterial stiffness** as assessed by pulse wave velocity in patients with chronic kidney disease and secondary hyperparathyroidism, Site investigator: Harish Puttagunta

**Comparison of Immunosuppressant Drug Pharmacokinetics in Indigenous versus non-Indigenous Australian Kidney Transplant Recipients.** (Partially Sponsor Funded) Site investigator: Suda Swaminathan

**REDUCTION – REDUcing the burden of dialysis Catheter ComplicaTIONS: a National approach,** (Partially Sponsor Funded) Site investigator: Suda Swaminathan

**FoWARD (FabRy testing in Western Australia Renal Dialysis), RPH CPI – Dr Mark Thomas** Site investigator: Suda Swaminathan.

---

**Respiratory Medicine**

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Medicine</td>
<td>23</td>
<td>4</td>
</tr>
</tbody>
</table>

**Projects: (23)**

- **Complications related to Indwelling Pleural Catheters:** Single center retrospective audit in FSH
- **COPD Assessment Test** is an appropriate Screening Test for Anxiety in COPD
- **End-of life care of Oncology inpatients** (The Canberra Hospital): Are we getting it right?
- **Severe Asthma Web-based Database (SAWD)** This is performed in partnership with the AustralAsian Severe Asthma Network and NHMRC Centre of Excellence for Asthma
- **Australian Mepolizumab Registry (AMR)**
- **International Lung Screen Trial** NHMRC funded multi-centre study
- **Lung Cancer Demonstration Project (LCDP)**
- **The Australasian Malignant Pleural Effusion (AMPLE) Trial 2**
- **PILOT Study – Pleural Infection Longitudinal Outcome Study**
- **An audit into pleural procedure practice & pleural fluid analysis** at Fiona Stanley Hospital 2015
- **Identifying risk factors that predict poor tolerance in pneumothoraces following transthoracic needle biopsy (TTNB) of lung lesions**

---

**Collaborative Projects (Interdepartmental): (1)**

**Sirolimus and microcytic anaemia:** Effect on iron utilization and inflammation as compared to calcineurin inhibitors. Investigators – A. Krishnan, J. Olynyk, S. Swaminathan. (Gastroenterology & Nephrology/Renal – Spinnaker Grant)

**Publications: (0)**

Nil

**Grants/funding:**

J. Olynyk 2016: Spinnaker Collaborative Partnership Grant/Fremantle Hospital Medical Research Foundation 2016 Research Award

Multiple Sponsors (including Pharmaceutical Sponsors).
Lymphangitis in mesothelioma: a single centre experience of a rare complication of mesothelioma

Retrospective audit of management of pleural infections in a newly established Tertiary hospital

Complications related to Indwelling Pleural Catheters: Single centre retrospective audit
Audit of the diagnosis and management of malignant pleural effusions at FSH
Audit of pneumothorax complication rate in patients undergoing CT guided lung biopsies
Does pharmacist intervention impact risk assessment and prophylaxis rates?
Lung transplantation – The West Australian Experience
Syphilis ,Swiss Cheese and Diagnostic Error – a case report
Retrospective audit of management of pleural infection as at a newly established Tertiary care hospital
EBUS Core biopsy in a two-step strategy: Diagnostic performance and adequacy for PD-1/PDL-1
Utility of endobronchial elastography in the staging of lung cancer.

Publications (4)

2016 (4)


Grants/funding:

Australian Mepolizumab Registry (AMR)

- International Lung Screen Trial NHMRC funded multi-centre study-NHMRC grant. WA Cancer and Palliative Care Network Fellowship: Dr KP Lim

- Lung Cancer Demonstration Project (LCDP) Cancer Australia.
## Rheumatology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatology</td>
<td>21</td>
<td>30</td>
</tr>
</tbody>
</table>

### Projects: (21)

- **A study of the symptoms and side effects of statins**: Dr Helen Keen
- **RCT of anti-inflammatory therapy in gout**: Dr Helen Keen
- **RCT of krill oil in knee OA**: Dr Helen Keen
- **Comparison of US< Fibroscan and AST/P***
- **Is undetectable Mannose Binding Lectin (MBL) a Risk Factor for Serious Infection (SI) in Rheumatoid Arthritis (RA)?** Graeme Carroll and a large team of collaborators
- **Which factors contribute to serious infections in the ARAD (Australian Rheumatology Association Database) rheumatoid arthritis cohort?** Reza Hamidravan (M Sc candidate, Charles Sturt University), Graeme Carroll, Prof Kenneth Russell and Dr Jalal Jazayeri.
- **Is MBL deficiency a risk factor for multiple (five or more) urinary tract infections (UTIs) in auto-immune diseases.** Dr Jasjit Walia (final year UND student) and Graeme Carroll
- **Does MBL deficiency predispose to Breast cancer in RA?** Dr Payal Goel, Dr Sophie Coleman, Prof Max Bulsara and Graeme Carroll
- **Is MBL deficiency associated with Bronchiectasis in RA?** Dr Krista Makin, Dr Sophie Coleman, Prof Max Bulsara and Graeme Carroll
- **Are TNF blockers effective in the treatment of DISH (Diffuse Idiopathic Skeletal Hyperostosis)?** Dr Graeme Carroll, Dr Justin Bui, Dr Bill Breidahl, Dr Swithen Song and Dr W Michael Dewing.
- **Is undetectable MBL a risk factor for septic arthritis or tenosynovitis?** Dr Graeme Carroll, Dr Kylan Pathmanathan, Prof Ken Russell
- **Prosthetic joint infections – which rheumatic disease patients get them and why?** A combined FSH and ARAD (Australia Rheumatology Association Database) initiative. (Helen Keen, Graeme Carroll Kylan Pathmanathan and Ben Clarke)
- **SAPHO – a long term clinical outcomes study.** Hong Yap, Graeme Carroll, Janet Roddy, Nicola Cook and D Robert Langlands
- **Is MBL deficiency a risk factor for Shingles (herpes zoster outbreak) in rheumatic diseases and does severe deficiency predict zoster ophthalmicus /cerebral vasculitis complicating the disease?** Dr Johnathan Hague and Dr Graeme Carroll
- **Is fibromyalgia a component of the Hypermobility / Ehlers Danlos Syndrome continuum?** Dr Graeme Carroll
- **Is the modified Gorlin sign useful for differentiating OA phenotypes?** Dr Graeme Carroll

A preliminary study of OA phenotypes in the ankle and foot: **Is heterozygosity for HFE genotypes predictive and could loss of heterozygosity contribute to disease pathogenesis?** – a HARI (Haemochromatosis Arthritis Research Initiative) project (global consortium) chief investigators. Dr Graeme Carroll and Dr Patrick Kiely (London)

Ten year retrospective review of the incidence of serious infections in patients with rheumatoid arthritis on biologic agents at tertiary hospitals in Western Australia – Dr Chanakya Sharma, Dr Helen Keen, Dr Graeme Carroll


Publications: 30 (17 in 2016; 13 in 2015)

2016 (17)

Bissell, Lesley-Anne; Hensor, Elizabeth MA; Koza, Lukasz; Mackie, Sarah; Bursa, Agata; Nam, Jackie; Keen, Helen; Villeneuve, Edith; Donica, Helena; Buch, Maya; Conaghan, Philip; Andrews, Jacqueline; Emery, Paul; Morgan, Ann. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis – results from the IDEA study. In press Rheumatology 2016 2016 Dec; 55(12):2181–2190.


Keen H, Davis W, Latokovic E, Drinkwater J, Nossent J, Davis T. Ultrasound detected

Hepatitis B screening and recommendations for patients on biologics: D Hydai, H Keen, J Edelman, IMJ 2016 (suppl 2).

L Host, HI Keen, DM Black, BD Black, LL Laslett, G Jones. Zoledronic acid does not slow spinal radiographic progression in those with radiographic osteoarthritis. (Suppl1) ARD 2016.


2015 (13)


Grants:

2016 – NHMRC APP1102732 – RCT of methotrexate in hand OA
2016 – Arthritis Australia Project Grant – RCT of anti-inflammatory therapy in Gout
2015 – UCB grant Assessment of the nail bed in psoriatic arthritis by ultrasound and MRI
2015 – NHMRC APP1127981 – RCT of krill oil in knee OA
2007– 2020 – ArthroCare for employment of a PT Research Officer (Dr Sophie Coleman PhD – miscellaneous GC projects.)

Patents:

GJ Carroll. Development of a calculator to determine the Risk of Serious Infections in Rheumatoid Arthritis. US patents 13/891,429 (work is proceeding to validate the device, test it prospectively and provide an App. for portable and other electronic devices).
Urology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urology</td>
<td>6</td>
<td>16</td>
</tr>
</tbody>
</table>

Projects: (6)

**BCG/MM (Phase 3 RCT)** – CPI Professor Dickon Hayne (Investigator initiated). Affiliation with ANZUP. Aim: To determine the efficacy and safety of MMC in addition to BCG in patients with non-muscle invasive bladder cancer (NMIBC).

**Pain Free TRUS B (Phase 3 RCT)** – PI Professor Dickon Hayne (Investigator initiated). Affiliation with ANZUP. Aim: To determine the efficacy and safety of inhaled methoxyflurane plus PILA alone in men undergoing TRUS biopsy of the prostate.

**NMIBC Symptom Index** – PI Professor Dickon Hayne (Investigator initiated). Affiliation with ANZUP. Aim: The aim of the Phase 1 study is to undertake in-depth qualitative interviews with: (1) a sample of patients with experience of receiving treatment for NMIBC, and (2) a sample of healthcare professionals. The information obtained will be used towards developing an item list that will form the basis of the new PRO symptom index.

**Improving Sexual Health of men with prostate cancer** (Phase 3 RCT) – PI Professor Daniel Galvao. (Investigator initiated). Affiliation with Edith Cowan University. Aims:

- Examine the efficacy of exercise as a therapy to aid in the management of sexual dysfunction in men with prostate cancer.
- Determine if combining exercise and psychosexual therapies results in more pronounced improvements in the sexual health of men with prostate cancer.
- Assess if any benefit of exercise and psychosexual therapies on sexual dysfunction in men with prostate cancer is sustained long term.

**ACCEPT database** – Cystectomy clinical database (Investigator driven). Affiliation with ANZUP.

**One Stop Prostate Clinic Patient Preferences** – PI Cynthia Hawks CN (Investigator initiated). Part of a planned Masters project with University of Western Australia.

Publications: 16 (10 in 2016; 6 in 2015)

2016 (10)


**Long term follow up of intravesical therapy of neurogenic detrusor activity.** H Bangash, A Abdul-Hamid, D Hayne, J Thavaseelan. BJU Int 2016 117 S3 p21

A Survey of patient attitudes towards the use of smart phone applications by health
care professionals for patient care and management. H Bangash, M Kuan, D Hayne. BJU Int 2016 117 S3 p22–23

Appropriate investigation and referral of remote patients to urology with visible haematuria. A Abdalla, H Bangash, S McCombie, D Hayne. BJU Int 2016 117 S3 p34–35

The One Stop Prostate Clinic – Evolution of a rapid access diagnostic service. S McCombie, C Hawks, M Brown, D Hayne. BJU Int 2016 117 S3 p58–59

Inconsistent renal cell carcinoma follow up in a tertiary cancer centre. Time for a different approach? H Bangash, S McCombie, E Botha, N Lawrentschuk, D Hayne. BJU Int 2016 117 S3 p75–76


2015 (6)


Delays in the diagnosis and treatment of bladder cancer in Western Australia. S McCombie, F Lee and D Hayne. BJU Int 2015 115 S4 26–27

The development of a radical cystectomy enhanced recovery pathway at Fremantle Hospital. S McCombie, T. Nack, J Wilmott and D Hayne. BJU Int 2015 115 S4 98–99


Grants/funding:

December 2015 – Cancer Australia (Nationally Competitive via NHMRC). Developing a patient-reported symptom index for non-muscle invasive bladder cancer (start date 30 June 2016).

CIA: Associate Professor Manish Patel. CIC Professor Dickon Hayne

June 2015 – WACPCN Special Grants. Project title: Advancing Cystectomy Care: an Enhanced recovery Pathway Trial (ACCEPT) – seed funding Dr Dwayne Chan and Professor Dickon Hayne

Jan 2015 – University of Sydney Bridging Support Grant 2015. NHMRC Project Grant: APP1080786: OPTIMUM: Optimising Perioperative Therapy in Muscle invasive Urothelial Malignancy. A phase 3 trial of cisplatin and gemcitabine (CG) vs accelerated MVAC (accMVAC) given before or after cystectomy. CIA Professor Martin Stockler, CIB Professor Ian Davis, CIC Professor Dickon Hayne, CID Associate Professor Shomik Sengupta, CIE Professor Howard Gurney, CIF Dr Andrew Martin, CIG Dr Sonia Yip.
Rockingham Peel Group
Anaesthetics

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaesthetics</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Projects: (1)

PADDI Trial – The Perioperative ADministration of Dexamethasone and Infection trial. WA

Coordinating Investigator: Professor Tomás Corcoran. Principle Investigator: Dr Sam Hillyard.

This research is being conducted by the, Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network, located at Monash University together with the Australian Society of Infectious Diseases (ASID) clinical research network.

This research has been initiated by specialist anaesthetists Professor Paul Myles and Professor Tomas Corcoran.

Diabetes and Endocrinology

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes and Endocrinology</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

Projects: (2)

Prevalence of Use of Technology in Patients with Type 1 Diabetes mellitus. Inpatients at Rockingham General Hospital Outpatient Diabetes Service. Point-prevalence study, investigator-led. Dr Shivlal David, Dr Ken Thong.

Use of the Hybrid Closed Loop System in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia. Randomised Clinical Trial, investigator-led. Chief Investigator: Dr Marie-Anne Burkhardt from PMH. This is a study conducted by PMH and performed across PMH and several adult diabetes sites including RGH.
Emergency Department

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Department</td>
<td>5</td>
<td>2</td>
</tr>
</tbody>
</table>

Projects: (5)

**The Primary Spontaneous Pneumothorax study (PSP).** The PSP project has now finished recruiting and has entered a follow-up phase that is being coordinated through the Centre for Clinical Research in Emergency Medicine (CCREM).

Williams et al. *A randomised controlled trial of Continuous Positive Airway Pressure (CPAP)* for the treatment of severe respiratory distress by ambulance paramedics in the pre-hospital setting. Investigator initiated.

Jacobs et al. *Functional status of survivors of out-of-hospital cardiac arrest (OHCA) in Perth,* Western Australia. A retrospective review of medical records for OHCA victims who survived to hospital admission (RPH, Sir Charles Gairdner Hospital, FH, Joondalup Health Campus and Princess Margaret Hospital) will be conducted and information about the patient’s neurological status ascertained. Investigator initiated.

Paul Bailey et al. Rationale: Current practice for patients who achieve return of spontaneous circulation (ROSC) but remain unconscious is for paramedics to administer 100% oxygen on route to ED via an inserted airway (Endotracheal tube or supraglottic airway device). The use of 100% oxygen in the first hours after resuscitation is largely one based on “tradition.” The administration of 100% oxygen in the hours after ROSC may increase neurological injury compared with a lower fraction of inspired oxygen (FiO2).

Aim: To determine whether reducing oxygen administration to target a normoxic level as soon as possible in comatose adults with ROSC following a non-traumatic OHCA, compared to current practice of maintaining 100% oxygen, improves survival rates at the time of hospital discharge.

**The Australian Snakebite Project (ASP).** This investigator driven study is being coordinated through the CCREM at RPH and is an Australia wide study. Within Western Australia in addition to RGH the study is being conducted at RPH, FSH, Armadale Health Service and the WA Country Health Service. The coordinating study principal investigator is Professor Geoff Isbister (Newcastle), Dr Jessamine Soderstrom in WA and the principal investigator at RGH is Dr Rod Ellis.

**Publications: (2)**


**Grants/funding:**

Nil
Intensive Care Unit

Projects: (4)

A multi-centre, cluster randomised, crossover, registry trial comparing the safety and efficacy of proton pump inhibitors with histamine 2 receptor blockers for ulcer prophylaxis in intensive care patients requiring invasive mechanical intervention. Chief Principle Investigator: Dr Edward Litton (FSH). Principle Investigators (RGH): Dr Kartik Atre, Dr Ravikiran Sonawane. Study duration (12 months): 02/05/2017 to 01/05/2018. Ethics and governance approved in 2016.

SPRINT SARI – Short period incidence study of severe acute respiratory infection Investigators: Dr. Ravikiran Sonawane, Sarah Gilbert RN, ICU. Investigator initiated- Multi-centre, International study

Exploring The Perspectives Of ICU Staff Regarding Hand Hygiene Compliance: A Qualitative Analysis In The City Of Perth In Western Australia. Author: Dr. Ravikiran Sonawane, Deborah MacGill

A survey of post-intensive care syndrome in patients discharged from ICU in WA. Investigators: Dr. Ravikiran Sonawane, Dr. Clinton Ellis. Investigator initiated – Sir Charles Gairdner Hospital and RGH ICU.

Publications:

Nil

Grants/funding:

Nil
# Mental Health

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental Health</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

## Brain and Behaviour (Youth Mental Health)

**Projects: (1)**

**Altitudes East West:** A randomised controlled trial of moderated online social therapy for carers of first episode psychosis clients in real world settings. Chief Investigator: Prof John Gleeson. Principal Investigators: Dr Ashleigh Lin, Dr Liza Hopkins. Investigators: A/Prof Mario Alvarez, Dr Peter Koval, Dr Paul Denborough, Dr Reeva Lederman, Prof Helen Herrman, Dr Sarah Bendall, Prof Sue Cotton. Investigator initiated.

## Mental Health

**Projects (2)**

‘Whose Insight is it Anyway’? A qualitative research design which aims to compare similarities and differences in the views of treatment of mental illness, held by patients and mental health care professionals. The project is investigator-initiated, and is being conducted by Dr. Daniela Vecchio, Dr. Matthew Sewell, Dr. Timothy Styles, and Prof. David Paul.

Exploring the role that anticonvulsant medications have in treatment of the behavioural and psychological symptoms of dementia in Western Australia. Investigators: Dr Karen Heslop (Curtin University), Dr Darshan Trividi (RGH), Dr Andrew Stafford (WA Dementia Training Centre), Professor Dianne Wynaden (Curtin University) and Ass/Prof Christopher Etherton-Beer (School of Medicine and Pharmacology RPH). SMHS HREC approval 8th November 2016. Other participating sites: Fremantle Hospital, Armadale Hospital and Bentley Hospital mental health services.

**Publications:**

Nil

**Grants/funding:**

Curtin University.
Orthopaedics

<table>
<thead>
<tr>
<th>Specialty/department/service</th>
<th>Projects</th>
<th>Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental Health</td>
<td>*0</td>
<td>0</td>
</tr>
</tbody>
</table>

Projects:

*multiple collaborative projects – refer to [FSFHG Orthopaedics](#) section.
Appendix 1: Report template

Research Annual Report Template

Department:

Achievements over last two years:
One to two paragraph summary including any successful translation into clinical practice, awards

Current projects:
List, title, investigators, commercial or investigator initiated, lay summary

Outputs:
Publications
Presentations – place, date, title of conference (invited/oral or poster)
Commercialisation or other

Inputs:
Grants
Other funding
Appendix 2: Data source

Data regarding research projects is captured in multiple ways currently in the SMHS REG Unit:

- An Access database containing historical research information from manual files
- Excel database which contains the post transition tracker details
- Research Governance Service web based system.

Data for the overview of SMHS research activity was obtained from the REG Unit Access database “Research Ethics and Governance DB for Report Interrogation”, on 18 September 2017.

Ethics approvals:

Health Research Ethics Committee (HREC) approvals have been included where the approval date (as contained in the “HREC approved” database field) is between 01 January 2015 and 31 December 2016, and

- the lead HREC is within SMHS, or was within SMHS at the time of approval. Notably, RPH moved from SMHS to EMHS during this time.
  - or –
- the site for which the ethics approval was granted is within SMHS, or was within SMHS at the time of approval.

Note that if two (or more) sites within SMHS were approved at different times for the same project, this is considered to be two (or more) approvals, as the approval date is different.

Governance approvals:

All governance approvals have been included where the approval date (as contained in the “Site Authorisation Date” database field) is between 01 January 2015 and 31 December 2016, and approval was obtained for a site within SMHS. The approval date is the date that appears on the site approval letter, as signed by the relevant site Executive Director.

Project closures:

The first notification of project closure from a researcher is to Ethics; therefore this date (as contained in the “Date Closed” database field) has been used.

The number of projects closed is unexpectedly low when compared to the governance approvals. The reasons for this are not clear from the data.